Genome-wide association studies (GWAS) have identified over 100 risk loci for schizophrenia, but the causal mechanisms remain largely unknown. We performed a transcriptome-wide association study (TWAS) integrating expression data from brain, blood, and adipose tissues across 3,693 individuals with schizophrenia GWAS of 79,845 individuals from the Psychiatric Genomics Consortium. We identified 157 genes with a transcriptome-wide significant association, of which 35 did not overlap a known GWAS locus; the largest number involved alternative splicing in brain. 42/157 genes were also associated to specific chromatin phenotypes measured in 121 independent samples (a 4-fold enrichment over background genes). This highthroughput connection of GWAS findings to specific genes, tissues, and regulatory mechanisms is an essential step toward understanding the biology of schizophrenia and moving towards therapeutic interventions.
and variation in cis-regulatory elements marked by chromatin ( Figure 1A ). We used population-level ChIP-H3k4me1 (enhancers), H3k4me3 (promoters), and DNAse (open chromatin) 6 , and in 45 HapMap CEU LCLs biases would not be expected to inflate the combined test across all individuals. Taken together, the allele-48 specific signal from both molecular phenotypes nominates the alternative allele at rs61764202 as disrupting 49 chromatin activity, increasing MAPK3 expression, which in turn decreases SCZ risk. genetic covariance (cov g ) between SCZ and the two molecular phenotypes (see Methods). Conceptually, 48 the genetic effect of a given molecular phenotype on SCZ will be attenuated by environmental noise, which 49 will manifest itself as lower cov g to SCZ for phenotypes further along the molecular cascade. We estimated 50 expression-SCZ and chromatin-SCZ cov g in the CEU and YRI samples with both chromatin and expression association; or frequency < 1%. Principal components (PCs) were computed using all samples for the NTR, 23 YFS, and METSIM data directly and using SNPweights (v2.1) 54 for the CMC data, outliers were removed 24 (samples > 6 standard deviations away the mean along any top component), and PCs included as fixed-25 effects in estimating h 2 g . For all datasets, related individuals with GRM values > 0.05 were also removed 26 prior to estimating h 2 g . 27 h 2 g estimation 28 Cis and trans h 2 g were estimated using variance-components, modeling the phenotype as a multi-variante 29 Normal y ∼ σ 2 g,cis K cis + σ 2 g,trans K trans + σ 2 e I where K are the standard genetic relatedness matrices from 30 SNPs in the cis locus (K cis ) and in the rest of the genome (K trans ). The σ 2 parameters were fit for each 31 gene using AI-REML as implemented in the GCTA software 55 , with principal components and sex included 32 as fixed effects. For h 2 g of differentially spliced introns, the intron ratios condition out isoform abundance 33 but total gene expression was also included as a covariate to account for any residual correlation. As in 34 previous studies 26 , individual estimates outside the plausible 0-1 range were allowed in order to achieve 35 unbiased mean estimates. The standard error of each estimate was approximated as the standard deviation 36 divided by the square root of the number of genes tested; however, significant differences were confirmed by 37 permutation tests (see below).
38
To evaluate the contribution of low-frequency variants, we imputed the NTR data to the Haplotype Reference 39 Consortium reference, yielding high-quality imputed SNPs down to MAF of 0.001. On average, we did not 40 observe a significantly non-zero contribution of imputed rare variants to cis-h 2 g , nor did we see a significant 41 change in common cis-h 2 g due to denser imputation relative to array SNPs (Table S1 ). Though recent work eQTL effect sizes between cases and controls and motivating us to use the full cohort as a TWAS reference is a matrix of principal components accounting for ancestry. The risk-score accuracy was then measured as locus using individuals with both expression and chromatin measured. To evaluate power at genome-wide 23 significance, a TWAS association was reported as significant if it had P < 0.05 after correcting for (average 24 30 peaks per locus) × (20,000 genes) = 600,000 tests. For the QTL-based approach, given M SNPs in 25 the locus, a SNP was reported as significant if it had an eQTL P < 0.05 after correcting for M × 20, 000 26 tests and a cQTL P < 0.05 after correcting for M × 30 × 20, 000 tests. For a given chromatin sample 27 size, the simulation was then performed at 100 random loci and 5 random seeds each, with the fraction 28 of loci reported as significant by each method taken as the power ( Figure S14 ). The TWAS simulation 29 was separately performed under the null, using non-heritable chromatin and expression, and shown to be 30 well-calibrated under the null (Figure s13 ).
31
Individual-level chromatin TWAS 32 We used cis SNP-expression effect sizes computed by BSLMM scores in the four expression reference panels 33 (including differentially spliced introns) to predict individual-level expression in the 45 CEU 18 and 76 6 YRI 34 individuals with measured chromatin phenotypes. We retained only SNPs that were typed in both studies 35 and removed strand-ambiguous SNPs. We did not perform any additional QC of the functional features, 36 which were all previously PEER-adjusted and normalized 6, 18 . We note that even though the YRI target 37 samples are of different ethnicity, this prediction does not require an LD-reference panel and is therefore 38 only expected to suffer loss in power (but not increased type I error) due to the differences in LD. For each 39 predicted gene, we identified all chromatin peaks within a given window of the TSS (primary results used 40 ±500kb) and tested each mark for association to predicted expression by linear regression.
41
Multiple hypothesis correction for chromatin TWAS 42 The large number of correlated phenotypes analyzed -expression from five experiments and chromatin from 43 nine experiments in two populations -allows for several approaches to multiple testing correction. For 44 the chromatin TWAS, we corrected for the number of gene-peak pairs tested within a single expression 45 reference and chromatin phenotype experiment (for example, number of gene-peak pairs when evaluating 46 predicted CMC expression with the CEU:H3k27ac chromatin phenotype). This is directly comparable to the experiment-wide corrections applied in previous eQTL/cQTL analyses 6, 18 . The same correction was applied for the SCZ/chromatin TWAS overlap: for example, the 44 SCZ TWAS genes identified using 1 CMC expression were within 500kb of 1,528 total peaks in the CEU:H3k27ac experiment and "overlap" was 2 reported for any peak that had a chromatin TWAS association P < 0.05/1, 528.
3 For comparison, we separately calculated the number of associations that were significant at 5% FDR across 4 all molecular experiments. This yielded approximately 3.5× more chromatin TWAS associations and 1.2× 5 more SCZ and chromatin TWAS associations (Table S2 ), demonstrating that the above experiment-wide 6 Bonferroni correction strategy corresponds to a conservative study-wide FDR. 7 eQTL/cQTL overlap analysis 8 We compared the chromatin TWAS to the traditional approach of identifying SNPs that are significant 9 both as cQTLs and eQTLs in real data ( Figure 4B ). For each population and given distance to TSS, we 10 performed this analysis in two stages. Stage 1: We identified all eQTLs that were significant after Bonferroni 11 correction for the total number of SNP-gene pairs tested. When distance to TSS was the maximal allowed 12 (500kb), this resulted in 355 eQTLs in the YRI and 579 eQTLs in the CEU data. Stage 2: From the set 13 of significant eQTLs, we then looked for those that were also significantly associated with peaks from a 14 given chromatin phenotype (for peaks within the given distance to TSS), after Bonferroni correction for 15 the number of eQTL-peak pairs tested. In both stages the tests were only counted for the given chromatin 16 phenotype (e.g. H3K27ac in CEU). This was compared to the chromatin TWAS analysis where each gene 17 was tested against any peak within the given distance, and number of significant results reported after 18 Bonferroni correction for total number of gene-peak pairs tested. 19 Analysis of allele-specific expression 20 For each molecular phenotype (RNA-seq/ATAC-seq), we phased the locus using EAGLE2 59 and evaluated 21 haplotype allelic imbalance as follows. Given a "peak" SNP (for which there are RNA/ATAC-seq reads) and a "target" SNP (for which we want to evaluate allelic imbalance) we restricted to individuals that were 23 heterozygous for both SNPs and counted the number of peak reads mapping to the REF/ALT haplotypes 24 of the target SNP. We then assessed statistical significance for deviation from 50% balance using a binomial 25 test. When the peak SNP and target SNP are identical, this is equivalent to a standard allelic-imbalance 26 test across all heterozygous carriers in the peak. Duplicate reads were removed using samtools prior to all 27 analyses and only variants with ≥ 10 reads at the peak SNP were tested. See Supplementary Materials for 28 details on individual phenotypes analyzed.
29
Ratio of cis-genetic covariance between chromatin-SCZ and expression-SCZ 30 To shed more light on the potential causal model, we sought to evaluate the evidence in support of two models To compare these two models without bias from sample size or assay, we estimated the genetic covariance 37 (cov g ) using the PGC SCZ summary statistics and molecular data from the CEU/YRI individuals which 38 had both chromatin and gene expression measured. For each SCZ/chromatin TWAS gene, we defined the 39 target locus as ±50kb of the union of gene and peak boundary and estimated SCZ-chromatin and SCZ-40 expression cov g using cross-trait LD score regression 50 , restricting to the well-imputed HapMap3 SNPs and 41 using in-sample LD. To estimate significance, background cov g was computed using the same procedure over 42 200 randomly gene-peak pairs within 500kb of the TSS. The observed and background estimates were then 43 compared using the non-parametric Kolmogorov-Smirnov test. We note that for the YRI samples LD in the estimate of cov g ; however, because the random gene-peak pairs are also computed from the same population, 1 we do not expect significance measured against this null to be inflated. We separately considered a partial 2 correlation analysis, where each expression measurement was transformed to the residual of the associated 3 chromatin peak in a standard linear regression (and likewise for each chromatin measurement). The two 4 estimates of cov g were again computed from these partial phenotypes as described above. We caution that 5 the estimate of e in the above equation was computed from an average across all loci, and could also be 6 consistent with confounding from different levels of measurement error for ChIP-seq and RNA-seq, a mixture 7 of models M CH and M EX that favors model M CH , or mediation by other unobserved molecular phenotypes. 
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−log10 PThe PGC data was randomly split into increasingly large discovery samples (size on the x-axis) and TWAS statistics were estimated from each reference panel.
Left panel reports the number of significant genes (after 5% FWER correction) for a given GWAS sample size. Right panel reports the slope from a regression of β replication ∼ β discovery for significant genes identified at each sample size (where all 56, 000 − x remaining samples were used as replication). (b) TWAS effectsizes for association to schizophrenia identified in the PGC (x-axis) compared to corresponding estimates in the CMC (y-axis). Dotted line corresponds to y = x; red line corresponds to the slope from a (Z-score weighted) regression of CMC ∼ PGC, with estimate and p-value shown in bottom right. (c) Schizophrenia risk prediction R 2 shown for risk scores constructed from significant TWAS genes (bars) and PGC2 GWAS SNPs (dashed line, comparable to the 1% − 3% reported in ref 1 ). Number of genes used in each score reported in parenthesis. Linear-regression R 2 of phenotype on predictor (after subtracting R 2 from jointly fit ancestry PCs) was transformed to the liability scale assuming schizophrenia prevalence of 1%, a linear transformation consistent across all predictors. (d) Schizophrenia risk prediction R 2 for polygenic gene risk scores across multiple significance thresholds. Significant correlations (after Bonferroni correction for number of thresholds tested) are indicated with a (*) and most significant P-value reported. Right-most panel shows prediction from all tissues jointly (black) and from CMC/brain genes + differentially expressed introns jointly (red). were simulated under the SNP → chromatin → expression model and two methods to detect gene-mark associations evaluated. (TWAS, orange) corresponds to predicting expression from a held-out reference panel with 1,000 individuals and testing each proximal chromatin peak for association. (eQTL/cQTL, green) corresponds to identifying SNPs that are significantly associated with both chromatin and expression at the locus. For a given chromatin phenotype sample size (x-axis), power was measured as the number of instances where locus was deemed significant after accounting for number of gene-mark pairs tested (TWAS) or number of SNPs and gene-mark pairs tested (eQTL/cQTL). Solid (dashed) lines correspond to 1 (2) chromatin-causing variants in the simulation. (b) Genes significantly associated with a chromatin phenotype peak in YRI/CEU. For a given distance from the gene (x-axis), the number of unique genes is reported after experiment-wide Bonferroni correction for tests across all chromatin phenotypes. Results from TWAS prediction-based approach shown on left; results from overlapping QTL approach on the right (see Methods).
